News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. Treasury's enlarged long-term buyback repurchased $5.187B but long-term yields rose to multi-week and multi-month highs.
  • QatarEnergy seeks 2–3 million tonnes per annum of U.S. LNG through 2031 to replace Ras Laffan capacity damaged by Iranian strikes.
  • Federal banking regulators released proposed principles-based third-party risk guidance and opened a 60-day comment period.
  • Colgate-Palmolive engaged Goldman to explore a >$1B carve-out sale of Softsoap, Irish Spring and Speed Stick.
  • Casablanca's All Shares index fell 0.91% as utilities, banking and mining sectors declined amid weaker crude and currency moves.
  • Warsaw stocks rose as basic materials, construction and energy led gains, with the WIG30 index up 0.64%.
  • An apparent institutional buyer established large Nov. 2026 SPIE option positions signaling bullishness ahead of analyst upgrades.

Latest Articles

Plains All American Reports Second-Quarter 2026 Results

Plains All American Reports Second-Quarter 2026 Results

Plains All American Pipeline, L.P. (Nasdaq: PAA) and its parent Plains GP Holdings reported strong second-quarter 2026 financial results, highlighted by $1.830 billion net income attributable to PAA, including a $1.6 billion gain from the Canadian NGL Business divestiture. The company reduced debt by approximately $2.9 billion, achieving a pro form…

ACM Research Shares Jump After Quarter Beats Estimates, Guidance Raised

ACM Research Shares Jump After Quarter Beats Estimates, Guidance Raised

ACM Research jumped 14.0% in pre-market trading after reporting second-quarter results that outperformed analyst estimates on both earnings and revenue. The company posted EPS of $0.61 versus a $0.42 consensus and revenue of $292.92 million against expectations of $269.24 million, while raising the lower end of its full-year 2026 revenue guidance a…

Corsair Shares Jump After Q2 Beat, Margin Record and Higher Guidance

Corsair Shares Jump After Q2 Beat, Margin Record and Higher Guidance

Corsair Gaming stock rallied sharply in pre-market trading after the company posted second-quarter 2026 results that materially outperformed analyst expectations. The company reported non-GAAP EPS of $0.23 versus a consensus near $0.09, revenue of $314.3 million, and record gross margin of 33.2%. Management also raised the low end of full-year reve…

Guardian Pharmacy Services Stock Pops After Q2 Beats, Raises Revenue Outlook

Guardian Pharmacy Services Stock Pops After Q2 Beats, Raises Revenue Outlook

Guardian Pharmacy Services saw its shares rise in pre-market trading after reporting second-quarter 2026 results that topped analyst expectations on both earnings and revenue. The long-term care pharmacy operator beat consensus adjusted EPS and posted modest year-over-year revenue growth that management said would have been substantially higher abs…

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

Treace Medical Concepts, a Nasdaq-listed medical technology company specializing in bunion surgical treatments, reported Q2 2026 revenue of $45.4 million, down 4% year-over-year, with a net loss of $15.9 million. The company reduced cash usage by 57% year-to-date and improved adjusted EBITDA loss slightly. It initiated limited releases of new produ…

FRSPF: Why a Short-Covering Breakout Could Drive a Swing Trade

FRSPF: Why a Short-Covering Breakout Could Drive a Swing Trade

First Phosphate (FRSPF) is an OTC microcap that has seen a meaningful drop in short interest over the past months while technicals are turning bullish. Coupled with visible short-volume spikes and above-average liquidity for an OTC name, the setup favors a tactical long: a momentum-driven short-covering run could lift the stock through key moving a…

Purple Biotech Reports Second Quarter 2026 Financial Results

Purple Biotech Reports Second Quarter 2026 Financial Results

Purple Biotech Ltd. reported strong preclinical results for its tri-specific antibody candidate IM1240, demonstrating favorable anti-tumor activity, safety profile, and pharmacokinetics. The company is preparing for first-in-human clinical studies in 2027. With $6.1 million in cash as of June 30, 2026, Purple Biotech has a runway through mid-2027, …

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems announced its financial results for Q2 2026, showing total revenue of $8.1 million, an 11% growth year-over-year, driven by increased placement and validation of Growth Direct systems. The company achieved record gross margins of 15%, improving significantly from the prior year, and reaffirmed its full-year 2026 revenue guida…

WRAP Completes Training Foundation of WrapShield™ – WrapTactics™ Launches as the Operational Backbone of Non-Lethal Response

WRAP Completes Training Foundation of WrapShield™ – WrapTactics™ Launches as the Operational Backbone of Non-Lethal Response

Wrap Technologies announced the commercial launch of WrapTactics™, a Learning Management System that completes the training foundation of their WrapShield™ six-tier non-lethal response platform. Following ATF's classification of BolaWrap® 150 as a non-lethal instrument of restraint, WrapTactics™ provides essential training and certification, enabli…

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

NRx Pharmaceuticals announced that the FDA finished the first-cycle review of its ANDA application for preservative-free ketamine, identifying no major deficiencies related to the drug or its manufacturing, labeling, or chemistry. The only remaining issue pertains to packaging certification, specifically the luer lock vial, which is already used in…

Ultralife Corporation Reports Second Quarter Results

Ultralife Corporation Reports Second Quarter Results

Ultralife Corporation reported second quarter 2026 results featuring $47.9 million in sales, a slight 1.3% revenue decline from the prior year but an improved gross profit margin of 28.9%. The company achieved GAAP EPS of $0.15, tripling from $0.05 in the prior year quarter, and adjusted EBITDA rose 48% to $6.1 million. Backlog hit an all-time high…

ARKO Corp. Reports Second Quarter 2026 Results

ARKO Corp. Reports Second Quarter 2026 Results

ARKO Corp., a major U.S. convenience store and fuel wholesaler operator, reported its Q2 2026 results with decreased net income but increased Adjusted EBITDA. The company reaffirmed its full-year Adjusted EBITDA guidance and highlighted progress on transformation initiatives including dealerization, remodels, and loyalty programs. Post-quarter, ARK…

Johnson Outdoors Reports Fiscal Third Quarter Results

Johnson Outdoors Reports Fiscal Third Quarter Results

Johnson Outdoors Inc. announced its fiscal third quarter results ending July 3, 2026, reporting a 5% increase in net sales to $189.7 million, driven primarily by strong performance in its Fishing and Diving segments. Operating income more than doubled to $18.3 million aided by tariff refunds, improved margins, and pricing actions. Year-to-date resu…

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics announced its second quarter 2026 financial results, reporting Q2 revenue of $29.1 million and a GAAP basic loss per share of $0.12. The company affirmed its full-year 2026 revenue guidance of $100.5 to $111.0 million. Key business updates include the acceptance of the NDA for F351 (hydronidone) for chronic hepatitis B-induced liv…

Alphatec Rebound Trade: Buy the Delivery Recovery Narrative

Alphatec Rebound Trade: Buy the Delivery Recovery Narrative

Alphatec (ATEC) cratered after a May earnings report that flagged installation timing issues and missed EOS unit deliveries. The stock has stabilized and is showing bullish technicals while trading at a cheaper revenue multiple than the 2025 peak. This is a tactical long: enter on a gentle dip, use a tight stop to respect execution risk, and target…